NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
An Open, Single treatment arm, Multi-center, Prospective, Phase 2 Trial to Evaluate Efficacy and Safety of NB02 (Poseltinib) combined with Rituximab and Lenalidomide as a Salvage Therapy for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
Primary CNS Lymphoma (PCNSL)
DRUG: R2P -> RP
Overall Response (ORR) by IRC, End Of Induction, 4 cycles (12 weeks)
Overall Response by Investigator (ORR), End Of Induction, 4 cycles (12 weeks)|Overall Survival (OS), End of Study, through study completion, an estimation of 2 years|Progression Free Survival (PFS), End Of Treatment, through study completion, an estimation of 2 years|Event Free Survival (EFS), End Of Study, through study completion, an estimation of 2 years|Response Duration, End Of Treatment, through study completion, an estimation of 2 years|Time To Response, End Of Treatment, through study completion, an estimation of 2 years
For outpatients or inpatients who meet the criteria for subject selection, the study is conducted with patients who have given a sufficient explanation of the study and who voluntarily consented to participate in the study.

Patients enrolled in the study receive a combination therapy of NB02, Rituximab and lenalidomide according to the criteria specified in the protocol.

Induction(R2P) 21 days per cycles, 6 cycles

* NB02 : 60mg BID PO, Day 1-21
* Rituximab 375mg/m2 DAY IV Day 1, 8, 15 at 1st cycle; D1 at 2nd to 6th cycles
* Lenalidomide : 20mg QD PO, Day 1-14

Maintenance(RP) 21 days per cycles, until Progression

* NB02 : 60mg BID PO, Day 1-21
* Lenalidomide : 20mg QD PO, Day 1-14